SCHEMBL5536788

SCHEMBL5536788

Cc1ccc(C)c(OC2CCN(C)CC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46
SCN1A P35498 1/20 0.45
SCN2A Q99250 1/20 0.45
SCN3A Q9NY46 1/20 0.45
HRH3 Q9Y5N1 1/20 0.43
POLB P06746 1/20 0.43
SYK P43405 1/20 0.42
CYP2D6 P10635 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 2/20 0.41
NPY1R P25929 1/20 0.41
NPY2R P49146 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544941 0.87 HTR2C (0.49) HTR2CHTR2BSCN1ASCN2ASCN3A
SCHEMBL5536784 0.85 SYK (0.41) HTR2CHTR2BPOLBSYKKDM4E
SCHEMBL9921755 0.84 HTR2C (0.53) HTR2CHTR2BSCN1ASCN2ASCN3A
SCHEMBL4499692 0.84 FPR2 (0.41) HTR2CHTR2BHRH3SMN1; SMN2KDM4E
SCHEMBL15061995 0.84 SCD (0.47) HTR2CHTR2BHRH3SMN1; SMN2KDM4E
SCHEMBL4491187 0.84 HRH3 (0.44) HTR2CHTR2BSCN1ASCN2ASCN3A
SCHEMBL10196595 0.84 ACHE (0.52) HTR2CHTR2BSCN1ASCN2ASCN3A
SCHEMBL22350849 0.84 HTR2C (0.50) HTR2CHTR2BSCN1ASCN2ASCN3A
SCHEMBL12794525 0.82 ADRB2 (0.48) POLBSYKKDM4EALDH1A1TSHR
SCHEMBL8296638 0.81 ADRB2 (0.47) POLBSYKKDM4EALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HTR2C 2910/4885HTR2B 3791/4885SCN1A 2660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.